بيكالوتاميد تيڤع ١٥٠ ملغ
teva pharmaceutical indust.ltd - bicalutamide 150 mg - tablets - bicalutamide - in patients with locally advanced prostate cancer (t3-t4 any n m0 t1-t2 n+ m0) bicalutamide is indicated as immediate therapy either alone or as adjuvant to treatment by radical prostatectomy or radiotherapy. the management of patients with locally advanced non-metastatic prostate cancer for whom surgical castration or other medical intervention is not considered appropriate or acceptable.
ريزدرونات تيڤع ٣٥ ملغ
abic marketing ltd - risedronic acid as sodium 35 mg - tablets - risedronic acid - treatment of postmenopausal osteoporosis to reduce the risk of vertebral fractures. treatment of established postmenopausal osteoporosis to reduce the risk of hip fractures. prevention of osteoporosis in postmenopausal women with increased risk of osteoporosis. treatment of osteoporosis in men at high risk of fracture.
نورميتن ١٠٠
teva pharmaceutical indust.ltd - atenolol 100 mg - tablets - atenolol - management of angina pectoris and hypertension,including hypertension of renal origin. late intervention after acute myocardial infarction.
نورميتن ٥٠
abic ltd. - atenolol 50 mg - tablets - atenolol - management of angina pectoris and hypertension, including hypertension of renal origin. late intervention after acute myocardial infarction
تيڤعكوتان
teva pharmaceutical indust.ltd - clotrimazole 1 %; dexamethasone acetate 0.044 % - cream - dexamethasone - tevacutan is indicated for the treatment of mycotic infections of the skin complicated by inflammation and/or secondary infection.
موكسيپن فورتة ٥٠٠ ملغ
salomon,levin & elstein ltd - amoxicillin trihydrate 500 mg - capsules - amoxicillin - infections caused by amoxycillin - susceptible organisms. prevention of bacteremia in patients at risk of developing bacterial endocarditis.
اموكسكلاڤ تيڤع ٨٧٥ ملغ
salomon,levin & elstein ltd - amoxicillin as trihydrate 875 mg; clavulanic acid as potassium salt 125 mg - film coated tablets - ampicillin, combinations - short-term treatment of bacterial infections at the following sites: upper/lower respiratory tract infections, genito-urinary tract infections, skin and soft tissue infections, bone and joint infections, dental infections and other infections.